The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast CancerMartin Filipits, Christine Gruber-Rossipal, Elisabeth Müller‐Holzner et al.|Clinical Cancer Research|2014Cited by 219
Data from The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast CancerMartin Filipits, Michael Gnant, Torsten O. Nielsen et al.|Unknown|2023Cited by 0
Supplementary Table 1 from The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast CancerMartin Filipits, Michael Gnant, Torsten O. Nielsen et al.|Unknown|2023Cited by 0
Supplementary Table 1 from The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast CancerMartin Filipits, Michael Gnant, Torsten O. Nielsen et al.|Unknown|2023Cited by 0
Abstract P2-01-24: Immune activation of tumor cells and microenvironment as assessed by PD-L1 expression and interferon gamma signaling predict long term disease-free and overall survival: Results of the prospective randomized neoadjuvant ABCSG 34 trialUlrike Heber, Zsuzsanna Bagó-Horváth, Christian F. Singer et al.|Clinical Cancer Research|2025Cited by 0